Reply  by Fauchier, Laurent & Babuty, Dominique
LETTERS TO THE EDITOR
Sudden Death, Arrhythmic Events and
Measurements of Heart Rate Variability
Fauchier et al., in their recent report (1), have made an important
contribution to the use of heart rate variability for risk stratifica-
tion. However, I have some concerns about the data as presented.
Of concern in Table 3 in their article is the report that SDANN
was greater than SDNN in both of the groups with outcomes. This
reflects either a typographic or methodologic error. Also, in Table
3, mean rmsSD is much higher in the group with sudden death,
whereas ln HF is not different between the groups. This raises the
possibility that the high values for rMSSD are associated with
abnormal, nonrespiratory HRV, a phenomenon we have termed
“erratic sinus rhythm.” This possibility can be examined by looking
at the distribution of power in a power spectral plot or by plotting
heart rate tachograms and examining the pattern of heart rate
changes. Finally, in Table 3, Fauchier et al. (1) give values for ln
VLF power as computed by the Oxford scanner. In each case, VLF
power is even lower than HF power. Because VLF power is
ordinarily greater than LF power, which is greater than HF power,
it is clear that the Oxford scanner values for VLF are not
comparable to those reported by others who use research software.
Similarly, the relationship between this value of VLF and total
power, as described in the second paragraph of the discussion,
while conceivably valid for a 10-min window, cannot be compared
with the standard for 24-h–based total power, which reflects
primarily circadian rhythms, and cannot be obtained in a 10-min
window. The aforementioned tachograms, incidently, will also
reveal the presence of periodic respiration.
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REPLY
We welcome the opportunity to respond to the letter from Dr.
Stein regarding our article (1). Most of the considerations of this
letter are related to Table 3 in our study. These data were only
provided for general information about the patients with sudden
death and those with arrhythmic events or free of events. Because
the duration of follow-up is not taken into account, definitive
conclusion based on these data would certainly be inadequate.
Some of these patients may have low HRV, and may therefore be
considered to have a poor prognosis, but were free of events
because of a very short follow-up, as shown by the large standard
deviation of the duration of follow-up in this group (53 6 41
months). Therefore, analysis of variance was not performed on
these data. Moreover, we do not consider that rmsSD is really
higher in patients with sudden death (29 6 12 ms) as compared
with patients free of events (25 6 15 ms), and it is exactly similar
in patients with arrhythmic events (25 6 8 ms). The nonparamet-
ric Mann-Whitney U test on these data was also inadequate, but
found a nonsignificant p value when comparing rmsSD between
each group (p 5 0.4 to 0.9), because the difference is low as
compared with the standard deviation of this variable.
It may be surprising that SDA5 was superior to SDNN in
patients with outcomes. However, from a mathematic point of
view, it is certainly not impossible to see segments with a standard
deviation of their means superior to the standard deviation of the
overall series, particularly when the number of normal to normal
intervals is different in each segment, whether the heart rate is
different or after exclusion of ectopic beats or artifact. Table 1 gives
a simplified numeric example for confirmation.
Dr. Stein pertinently noticed that VLF was relatively low in
each group. Data were log-transformed after reviewing in the last
version of the article to achieve normal distribution. Calculation
was performed on the data in ms instead of ms2 for VLF, and we
apologize for this mistake. In fact, VLF was 6.9 6 1.1 ln ms2 in
patients free of events, 6.1 6 1.5 ln ms2 in patients with sudden
death and 6.6 6 1.3 ln ms2 in patients with arrhythmic events;
therefore, VLF was greater than LF and HF in each group. The
ratio of VLF to total power was calculated on data in ms2 before
the log transformation, as in the report of Mortara et al. (2).
Several complex phenomena may indeed participate to HRV in
clinical practice, in particular, in patients with congestive heart
Table 1. Three Segments of NN Intervals (in ms) of the Same
Duration (10,000 ms) with a Standard Deviation of the Means
of Each Segment Greater Than Standard Deviation of All NN
Intervals
1 2 3
1,000 830 1,260
1,005 825 1,255
1,000 840 1,245
995 830 1,235
990 845 1,250
995 815 1,260
995 830 1,255
1,005 830 1,240
1,010 840
1,005 830
835
850
Overall
Sum (ms) 10,000 10,000 10,000 30,000
Mean (ms) 1,000 833.33 1,250 1,027.78
SDNN (ms) 5.92 8.98 8.66 166.86
SD mean (ms) 171.23
NN 5 normal to normal RR intervals; SD 5 standard deviation.
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failure. We would be happy to collaborate with Dr. Stein to study
“erratic sinus rhythm” with a specific research software, because the
analogic tape of the ambulatory electrocardiograms of our patients
is still available. However, from a practical standpoint, we consider
that an important issue of our article is that our results were
obtained with a commercially available Holter monitoring system,
and with demonstration that SDNN, a simple and reproducible
measurement of HRV, is probably the most powerful for risk
stratification. These findings may have more direct implications for
identifying patients at risk and may guide subsequent investiga-
tions and therapy, either on an individual basis or as part of a
controlled clinical trial.
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Carvedilol in Class IV Heart Failure
Macdonald et al. (1) have reported favorably on the use of
carvedilol in patients with New York Heart Association functional
class IV heart failure. However, no mortality figures were stated.
Table 3, “Nonfatal Adverse Events,” indicates that 27 of 63
patients in functional class IV experienced adverse events, most
commonly worsening heart failure. But no information on the
number of deaths in the 63 patients is reported. On page 933,
“Actuarial Survival,” the statement is made that “the 1-year
mortality of 16 6 5% in this patient group treated with carvedilol
compares favorably with the mortality reported for similar patient
groups in other studies.” However, patients in functional class IV
heart failure with certain unfavorable characteristics were excluded.
The following were the exclusion criteria: cardiogenic shock,
intractable pulmonary or systemic edema, heart failure requiring
intravenous inotropic or mechanical support, bradycardia with
heart rate ,50 beats/min, systemic hypotension with blood pres-
sure ,80/50 mm Hg or chronic air flow limitation with evidence
of $20% reversibility in airway obstruction in response to inhaled
salbutamol. It would seem reasonable to expect that with these very
sick patients excluded from the treatment group, the mortality
figures in the remainder receiving carvedilol would be clearly
favorable in comparison to any control group, if carvedilol were
indeed beneficial.
Because adverse events with carvedilol therapy usually occur
early in the treatment course, it would be important to know not
only how many of the treated patients in functional class IV died,
but also the duration of their treatment before death. One would
anticipate that the deaths occurred early.
Additional data on the survival of patients in functional class IV
heart failure treated with carvedilol are clearly needed.
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We thank Dr. Hoffman for his comments. As stated in our report
(1), the actuarial survival rate for patients in New York Heart
Association functional class IV heart failure at one year was 84%
and the one-year mortality rate was 16%. Overall, 10 patients in
functional class IV died within the first year after commencement
of carvedilol. As shown in Figure 1 (page 926), the deaths occurred
throughout the year, with no apparent clustering at the time of
initiation or titration of carvedilol. Causes of death were judged to
be progressive heart failure in five patients and sudden cardiac
death in five patients. All five patients who died suddenly were
taking carvedilol at the time of their death and had been treated for
6, 74, 96, 127 and 203 days, respectively. Deaths from progressive
heart failure occurred at days 41, 46, 142, 153 and 259. Carvedilol
was withdrawn before death in all five patients who subsequently
died of progressive heart failure. The reason for withdrawal in all
five patients was worsening heart failure, and the period between
carvedilol withdrawal and death ranged from 23 to 228 days.
We recognize that not all patients in functional class IV heart
failure referred to our institution were challenged with carvedilol;
however, we believe our patients are comparable to those in class
IV included in the other studies that we have cited. For instance,
in the CONSENSUS Study (26) in which the 1-year mortality
rate for enalapril was ;40%, all patients had to be stable on
medical therapy for 2 weeks before trial entry. Patients on
intravenous inotropic therapy and mechanical support were ex-
cluded. Similarly, in the study of Lee and Packer (19), only
patients with stable chronic functional class IV heart failure were
included. The one-year mortality rate in this study for patients
receiving angiotensin-converting enzyme inhibitors was ;50%.
As stated in the Discussion of our report, we can only speculate
on the impact of carvedilol on survival; however, we believe that a
one-year mortality rate of only 16% compares favorably with
historic reports such as those cited. The recently published Cardiac
Insufficiency Bisoprolol Study (CIBIS-II) (2) provides the stron-
gest evidence to date that the beneficial effects of beta-blockers in
heart failure extend to patients who are in functional class IV at
baseline. Seventeen percent of 2,647 patients entered into
CIBIS-II were in functional class IV at baseline. Active treatment
with bisoprolol reduced mortality by 34% as compared with
placebo, with no significant difference between class III and class
IV. Patients with severe functional class IV heart failure and recent
instability were excluded from CIBIS-II, as in our study.
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